A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed 50 enrolled Akeso

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end point is safety. The secondary end point is efficacy.

Timeline

Start: 2021-04-01
Primary completion: 2024-02-28
Completion: 2024-02-28

Publications

Lou H, Cai H, Huang X, Li G, Wang L, Liu F, Qin W, Liu T, Liu W, Wang ZM, Li B, Xia Y, Wang J. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clin Cancer Res. 2024 Apr 15;30(8):1501-1508. doi: 10.1158/1078-0432.CCR-23-3162.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Cadonilimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Cadonilimab	Monoclonal antibody	15 mg/kg	Intravenous
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Cisplatin	Other / unclassified	50 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Indications

No indication recorded.